APLT News and Press, Applied Therapeutics Inc. From 06/22/22

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

One of the first catalysts to look for when trading penny stocks is news. Company headlines are some of the most prominent and easily accessible pieces of information. In most cases, sporadic moves in the market can be associated with significant updates from companies. Think of it as the f...

The European Medicines Agency (EMA) granted orphan medicinal product designation to Applied Therapeutics' (NASDAQ:APLT) AT-007 (gavorestat) to treat Galactosemia. Galactosemia is a rare, genetic metabolic disorder which affects the body's ability to convert galactose to glucose. ...

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-0...

Applied Therapeutics press release (NASDAQ:APLT): Q1 GAAP EPS of -$0.88. Cash and cash equivalents and short-term investments totaled $55.7 million as of March 31, 2022, compared with $80.8 million at December 31, 2021. For further details see: Applied Therapeutics GAAP EPS of -$0.88

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...

Sorbitol correlates with disease severity in patients with SORD Deficiency AT-007 treatment substantially reduced sorbitol levels in a pilot study in SORD Deficiency Sorbitol elevation results in mitochondrial dysfunction, neuronal loss, and climbing defects in a drosoph...

Applied Therapeutics Inc. (NASDAQ:APLT) traded at a new 52-week high today of $57.37. This new high was reached on above average trading volume as 6.2 million shares traded hands, while the average 30-day volume is approximately 295,000 shares. Applied Therapeutics Inc is a clinical-stag...

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentatio...

Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO&#x...